Abstract
Parkinsonian patients receiving long-term levodopa-carbidopa (Sinemet) therapy often develop fluctuations in motor performance. Although maintenance of stable levels of plasma levodopa by means of its continuous intravenous infusion diminishes these fluctuations, practical limitations attending this therapeutic approach have prompted continuing attempts to develop oral controlled release levodopa-carbidopa formulations. In a double-blind, crossover clinical trial, one such preparation, CR-5 (Merck, Sharp & Dohme), produced significantly less plasma levodopa variations and substantially improved motor performance over Sinemet in 15 patients with mild to moderate fluctuations, all but one of whom chose to continue on CR-5 therapy after the study. Eight patients with severe motor fluctuations could not adjust to this preparation during the open phase and consequently withdrew from the study. Subjectively, most patients noted the convenience of less frequent dosing, improved sleep, and the amelioration of early morning akinesia and dystonia.
| Original language | English |
|---|---|
| Pages (from-to) | 1010-1012 |
| Number of pages | 3 |
| Journal | Archives of Neurology |
| Volume | 44 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - 1987 |
Fingerprint
ASJC Scopus subject areas
- Arts and Humanities (miscellaneous)
- Clinical Neurology
- Neuroscience(all)
Cite this
Controlled Release Levodopa-Carbidopa (CR-5) in the Management of Parkinsonian Motor Fluctuations. / Juncos, J. L.; Fabbrini, G.; Mouradian, M. M.; Chase, T. N.
In: Archives of Neurology, Vol. 44, No. 10, 1987, p. 1010-1012.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Controlled Release Levodopa-Carbidopa (CR-5) in the Management of Parkinsonian Motor Fluctuations
AU - Juncos, J. L.
AU - Fabbrini, G.
AU - Mouradian, M. M.
AU - Chase, T. N.
PY - 1987
Y1 - 1987
N2 - Parkinsonian patients receiving long-term levodopa-carbidopa (Sinemet) therapy often develop fluctuations in motor performance. Although maintenance of stable levels of plasma levodopa by means of its continuous intravenous infusion diminishes these fluctuations, practical limitations attending this therapeutic approach have prompted continuing attempts to develop oral controlled release levodopa-carbidopa formulations. In a double-blind, crossover clinical trial, one such preparation, CR-5 (Merck, Sharp & Dohme), produced significantly less plasma levodopa variations and substantially improved motor performance over Sinemet in 15 patients with mild to moderate fluctuations, all but one of whom chose to continue on CR-5 therapy after the study. Eight patients with severe motor fluctuations could not adjust to this preparation during the open phase and consequently withdrew from the study. Subjectively, most patients noted the convenience of less frequent dosing, improved sleep, and the amelioration of early morning akinesia and dystonia.
AB - Parkinsonian patients receiving long-term levodopa-carbidopa (Sinemet) therapy often develop fluctuations in motor performance. Although maintenance of stable levels of plasma levodopa by means of its continuous intravenous infusion diminishes these fluctuations, practical limitations attending this therapeutic approach have prompted continuing attempts to develop oral controlled release levodopa-carbidopa formulations. In a double-blind, crossover clinical trial, one such preparation, CR-5 (Merck, Sharp & Dohme), produced significantly less plasma levodopa variations and substantially improved motor performance over Sinemet in 15 patients with mild to moderate fluctuations, all but one of whom chose to continue on CR-5 therapy after the study. Eight patients with severe motor fluctuations could not adjust to this preparation during the open phase and consequently withdrew from the study. Subjectively, most patients noted the convenience of less frequent dosing, improved sleep, and the amelioration of early morning akinesia and dystonia.
UR - http://www.scopus.com/inward/record.url?scp=0023428710&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023428710&partnerID=8YFLogxK
U2 - 10.1001/archneur.1987.00520220016008
DO - 10.1001/archneur.1987.00520220016008
M3 - Article
VL - 44
SP - 1010
EP - 1012
JO - Archives of Neurology
JF - Archives of Neurology
SN - 0003-9942
IS - 10
ER -